Psychedelics are making headlines as a revolutionary new area of the broader pharmaceutical market — particularly in relation to the treatment of mental health ailments.
The global antidepressant market alone was worth $15 billion in 2020 and is expected to grow to over $21 billion by 2030.
A major push is now happening in the psychedelics space with a particular focus on the hallucinogen “psilocybin” — aka, “magic mushrooms.”
Scientists believe that psilocybin’s unique compounds hold nearly unlimited potential in the treatment of neurological and psychiatric disorders within the broader scope of mental illness.
Scores of research studies are underway across multiple countries — including right here in the US — with encouraging results pointing to the viability of the psilocybin market.
Yet, as we enter 2023, many challenges lie ahead both medicinally and investment-wise in this nascent sector.
The question is… are psychedelics stocks a wise investment at this early stage?
Our FREE online report seeks to answer that all-important question plus a whole lot more.
Inside, you’ll also be introduced to some of the top psychedelics stocks and funds that are poised to lead the pack higher in 2023 and beyond.
Should investors be betting the pharm in 2023?
Simply read our FREE online report to find out.
Enter your email below and the report is yours FREE… ticker symbols and all!